Cancer BiologybioRxivPreprint
SHP2 Inhibition Abrogates MEK inhibitor Resistance in Multiple Cancer Models
Carmine Fedele, Hao Ran, Brian Diskin…·Kwan Ho Tang
This study shows that combining SHP2 and MEK inhibitors overcomes adaptive resistance in multiple cancer models, including KRAS-mutant and wild-type RAS cancers.
DOI 10.1101/307876